Sinovac Biotech Ltd - ADR

$6.47

$0.00 (0.00%)

As on 07-Jul-2026 16:00EDT

Market cap

info icon

$642 Mln

Revenue (TTM)

info icon

$-- Mln

P/E Ratio

info icon

6.7

P/B Ratio

info icon

1.8

Div. Yield

info icon

0 %

Value Research Rating

--

Quality Score fund-quick-summary-circle

Quality Score/10

Growth Score fund-quick-summary-circle

Growth Score/10

Valuation Score fund-quick-summary-circle

Valuation Score/10

Momentum Score fund-quick-summary-circle

Momentum Score/10

Sinovac Biotech - ADR Share Price

Compare

High: Low: Return:

Max: Min: Median:

Max: Min: Median:

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 6.47 High: 6.47

52 Week Range

Low: 6.47 High: 6.47

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-- Mln

  • ROEROE information

    0.3 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    0

  • Debt to EquityDebt to Equity information

    0.1

  • Book ValueBook Value information

    $44.6

  • EPSEPS information

    $-0.6

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    99,294,704

10 Years Aggregate

CFO

$15,178.86 Mln

EBITDA

$17,833.12 Mln

Net Profit

$8,654.39 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Sinovac Biotech - ADR
0.0 0.0 0.0 0.0 -- 0.0 1.1
BSE Sensex*
-8.8 0.6 1.8 -4.4 6.0 6.6 10.8
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 07-Jul-2026  |  *As on 28-Aug-2026  |  #As on 26-Oct-2023
Company
2025
Sinovac Biotech - ADR
0.0
S&P Small-Cap 600
4.0
BSE Sensex
9.1

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Sinovac Biotech - ADR

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes...  vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. 

  • Chairman, CEO, Pres, MD, GM & Sec.

    Dr. Weidong Yin

  • Chairman, CEO, Pres, MD, GM & Sec.

    Dr. Weidong Yin

  • Headquarters

    Beijing

  • Website

    http://www.sinovacbio.com

FAQs for Sinovac Biotech - ADR

The share price of Sinovac Biotech Ltd - ADR is $6.47 (NASDAQ) as of 07-Jul-2026 16:00 EDT. Sinovac Biotech Ltd - ADR has given a return of 0% in the last 1 years.

The P/E ratio of Sinovac Biotech Ltd - ADR is 6.66 times as on 07-Jul-2026.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
-10.80
0.15
2024
7.09
0.08
2023
-6.45
0.07
2022
--
--
2021
0.09
0.08

The 52-week high and low of Sinovac Biotech Ltd - ADR are Rs 6.47 and Rs 6.47 as of 30-Aug-2026.

Sinovac Biotech Ltd - ADR has a market capitalisation of $ 642 Mln as on 07-Jul-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Sinovac Biotech Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.

loading...
loading...